Breast cancer is categorized in three basic therapeutic groups associated with distinct molecular subtypes, based on the status of the estrogen receptor (ER), the progesterone receptor (PR), and the receptor tyrosine-protein kinase erbB-2 (ERBB2, a.k.a. HER2) [34]. This evidence concerns the gene PGR and breast cancer.